Helix BioMedix, Inc. is a peptide discovery and development biopharmaceutical company, which is focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. The Companyâs lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the bodyâs innate immunity.
More about the company